Tag: Beigene

FDA, Regulations

BeiGene’s Brukinsa receives FDA approval for chronic lymphocytic leukaemia

January 23, 2023


The FDA’s decision was based on two global head-to-head phase 3 clinical trials in which Brukinsa – a small molecule inhibitor of Bruton’s tyrosine kinase (BTK) – demonstrated superior efficacy against Janssen’s Imbruvica (ibrutinib) in patients with relapsed/refractory CLL or […]

Cell and Gene Therapy, Industry

Beigene expands into cancer cell therapy with Shoreline pact

June 9, 2021

Via: Biopharma Dive

Beigene has quickly become a force in cancer drug development, earning approvals in the U.S. and China for its targeted therapy Brukinsa and immunotherapy tislelizumab. The biotech is developing a slate of small molecule and antibody drugs aimed at several […]